Cagrilintide
What it is
Cagrilintide is a synthetic, lipidated analogue of amylin, the pancreatic hormone co-secreted with insulin. It has been studied in clinical trials, alone and in combination with semaglutide, and is supplied here as a research reagent.
Where it has been studied
- Amylin and calcitonin receptor pharmacology
- Food-intake and body-weight models in rodents
- Combination studies with GLP-1 receptor agonists
Selected literature
- Development of Cagrilintide, a Long-Acting Amylin AnalogueKruse T et al. · J Med Chem, 2021 · PMID 34288673
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialFrias JP et al. · Lancet, 2023 · PMID 37364590
- Amylin analogs for the treatment of obesity without diabetes: present and futurePanou T et al. · Expert Rev Clin Pharmacol, 2024 · PMID 39317404
PubMed records selected for relevance to the compound. They describe published research, not outcomes or uses.
